Shiraz Qureshi Shafi
Introduction
Basal cell carcinoma (BCC) is a slow-growing epithelial malignancy arising from the basal cells of the epidermis and adnexal structures. It accounts for 80-95% of all eyelid malignancies (1). While BCC has a low metastatic potential, lesions involving the eyelids carry particular clinical importance due to their proximity to critical ocular structures and the risk of tissue destruction, recurrence, and visual impairment.
Epidemiology
Eyelid basal cell carcinoma predominantly affects older adults, with incidence rates increasing with age (2). It is more common in individuals with fair skin and history of chronic ultraviolet (UV) exposure. Lesions occur most frequently on the lower eyelid, followed by the medial canthus, upper eyelid, and lateral canthus (3). The predilection for the lower eyelid reflects increased exposure to sunlight (4).
Key risk factor includes cumulative UV radiation, light skin phototypes, male sex, immunosuppression, previous radiation exposure, and genetic predispositions such as basal cell nevus syndrome (Gorlin syndrome) (5). Unlike squamous cell carcinoma, BCC is rarely metastatic but local invasion can happen, particularly in recurrent lesions.
Pathophysiology
Basal cell carcinoma develops as a result of dysregulation of the hedgehog signalling pathway, most commonly due to mutations in the PTCH1 tumour suppressor gene or activating mutations in the SMO gene (6). These molecular alterations lead to the uncontrolled proliferation of basal cells and tumour formation.
Histologically, eyelid BCC demonstrates nests or chords of basaloid cells with peripheral palisading and retraction artefact. Several sub types exist including nodular, superficial, infiltrative, morpheaform, and micronodular variants (7). Infiltrative and morpheaform subtypes are associated with a higher risk of recurrence due to indistinct margins and deeper tissue invasion (1,8).
Clinical presentation
Basal cell carcinoma of the eyelid often presents insidiously and may be mistaken for benign lesions in early stages. Common clinical features include a slowly growing, pearly or flesh coloured nodule, often with telangiectasia and central ulceration. Loss of eyelashes (madarosis), lid margin distortion, and recurrent bleeding or crusting are important warning signs (7).
Lesions at the medial canthus are a particular concern due to the risk of deep orbital invasion along the lacrimal drainage system (9). Advanced disease may present with lid malposition, epiphora, diplopia, or visual disturbance, reflecting local tissue destruction or orbital involvement.
Diagnostic evaluation
Diagnosis of eyelid basal cell carcinoma is primarily clinical, supported by histopathological confirmation (10). A full thickness incisional biopsy is recommended to established diagnosis and tumour subtype prior to definitive management.
Imaging is not routinely required for small, well-defined lesions but may be indicated in cases of suspected deep invasion, recurrent disease, or medial canthal involvement. MRI or CT scans can assist in assessing orbital extension and involvement of adjacent structures.
Management
The primary goal of management is complete tumour eradication while preserving eyelid function and cosmesis. Treatment choice depends on tumour size, location, histological subtype, patient factors, and available expertise.
Surgical excision remains the gold standard. Mohs micrographic surgery is widely regarded as the treatment of choice for high-risk periocular BCC due to its superior margin control and lower recurrence rates (11,12). Standard excision with predetermined margins may be appropriate for small, low risk lesions, followed by appropriate reconstructive techniques.
Non-surgical options may be considered in selected cases. These include radiotherapy for patients unfit for surgery, topical therapy such as imiquimod for superficial lesions, and photodynamic therapy (13). However, these approaches are generally associated with higher recurrence rates and limited applicability in eyelid disease.
Prognosis and follow-up
The overall prognosis for eyelid basal cell carcinoma is excellent when diagnosed and treated early (14). Local recurrent rates are low following complete excision particularly with Mohs surgery. However, lifelong surveillance is recommended as patients are at increased risk of developing subsequent BCC’s and other skin malignancies.
Regular follow-up allows for early detection of recurrence and monitoring of eyelid function, tear drainage, and ocular surface health. Patient education regarding sun protection and self-examination plays a critical role in long-term disease prevention.
Conclusion
Basal cell carcinoma of the eyelid is a common yet potentially destructive malignancy that requires timely recognition and appropriate management. Advances in surgical techniques and molecular understanding have improved outcomes, emphasising tissue conservation and functional preservation.
References
1. Ben Simon GJ, Lukovetsky S, Lavinsky F, Rosen N, Rosner M. Histological and Clinical Features of Primary and Recurrent Periocular Basal Cell Carcinoma. ISRN Ophthalmol. 2012 Apr 24;2012:354829.
2. Paavilainen V, Tuominen J, Pukkala E, Saari KM. Basal cell carcinoma of the eyelid in Finland during 1953−97. Acta Ophthalmol Scand. 2005;83(2):215–20.
3. Pieh S, Kuchar A, Novak P, Kunstfeld R, Nagel G, Steinkogler F. Long term results after surgical basal cell carcinoma excision in the eyelid region. Br J Ophthalmol. 1999 Jan;83(1):85–8.
4. Cook BE, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies: an evidence-based update. Ophthalmology. 2001 Nov;108(11):2088–98; quiz 2099–100, 2121.
5. Gutierrez MM, Mora RG. Nevoid basal cell carcinoma syndrome: A review and case report of a patient with unilateral basal cell nevus syndrome. J Am Acad Dermatol. 1986 Nov 1;15(5, Part 1):1023–30.
6. Chmiel P, Kłosińska M, Forma A, Pelc Z, Gęca K, Skórzewska M, et al. Novel Approaches in Non-Melanoma Skin Cancers—A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC). Cells. 2022 Oct 12;11(20).
7. Puckett Y, Steele RB. Basal Cell Carcinoma. StatPearls. 2025;
8. Wade TR, Ackerman AB. The many faces of basal-cell carcinoma. J Dermatol Surg Oncol. 1978 Jan;4(1):23–8.
9. Rush JL, Nijhawan RI. Basal cell carcinoma invasion of the lacrimal system. JAAD Case Rep. 2020 Mar 25;6(4):276–8.
10. Margo CE, Waltz K. Basal cell carcinoma of the eyelid and periocular skin. Surv Ophthalmol. 1993;38(2):169–92.
11. Mohs FE. Mohs micrographic surgery. A historical perspective. Dermatol Clin. 1989 Oct;7(4):609–11.
12. Golda N, Hruza G. Mohs Micrographic Surgery. Dermatol Clin. 2023 Jan;41(1):39–47.
13. Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2007 Aug;245(8):1217–20.
14. Burgic M, Iljazovic E, Vodencarevic AN, Burgic M, Rifatbegovic A, Mujkanovic A, et al. Clinical Characteristics and Outcome of Malignant Eyelid Tumors: A Five-Year Retrospective Study. Med Arch. 2019 June;73(3):209–12.